Plain-language summary available for the TORREY seralutinib study

Seralutinib is a molecule that blocks inflammation, cell proliferation, and scarring responsible for pulmonary arterial hypertension. The Phase 2 TORREY study looked at whether inhaled seralutinib may be an effective and safe treatment for pulmonary arterial hypertension.

After 24 weeks, participants in the TORREY study who took seralutinib lowered the resistance to blood flow through the lungs by 14% more than those who took the placebo.

Research is continuing because of the positive TORREY study results, with the phase 3 PROSERA study now underway.

Read a plain-language summary of the TORREY study results